schliessen

Filtern

 

Bibliotheken

Synergistic benefit in inflammatory arthritis by targeting I B kinase   and interferon

Objectives: The IκB kinase (IKK)-related kinase IKK[epsilon] regulates type I interferon expression and responses as well as proinflammatory mediator production. We examined the role of IKK[epsilon] in arthritis and its ability to enhance the therapeutic response to systemic interferon (IFN) β thera... Full description

Journal Title: Annals of the rheumatic diseases 2009-02-01, Vol.68 (2), p.257
Main Author: M Corr
Other Authors: D L Boyle , L Ronacher , N Flores , G S Firestein
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: London: BMJ Publishing Group LTD
ID: ISSN: 0003-4967
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_journals_1777857511
title: Synergistic benefit in inflammatory arthritis by targeting I B kinase   and interferon
format: Article
creator:
  • M Corr
  • D L Boyle
  • L Ronacher
  • N Flores
  • G S Firestein
subjects:
  • Arthritis
  • Chemokines
  • Cytokines
  • Disease
  • Gene expression
  • Histology
  • Inflammation
  • Kinases
  • Laboratory animals
  • Ligands
  • Proteins
  • Rodents
  • Software
  • Tumor necrosis factor-TNF
  • Variance analysis
ispartof: Annals of the rheumatic diseases, 2009-02-01, Vol.68 (2), p.257
description: Objectives: The IκB kinase (IKK)-related kinase IKK[epsilon] regulates type I interferon expression and responses as well as proinflammatory mediator production. We examined the role of IKK[epsilon] in arthritis and its ability to enhance the therapeutic response to systemic interferon (IFN) β therapy in passive murine K/BxN arthritis. Methods: IKK[epsilon]â[euro]"/â[euro]" , IFNαâ^¼ βRâ[euro]"/â[euro]" and wild type mice were given K/BxN serum and treated with polyinosinic polycytidylic acid (poly(I:C)), IFNβ, or normal saline. Clinical response and histological scores were assessed. Gene expression in the paws was measured by quantitative PCR. Serum interleukin 1a receptor agonist (IL1Ra) and IL10 were measured by ELISA and multiplex bead array. Results: Arthritis was almost completely blocked in wild type mice if arthritogenic K/BxN serum and the Toll-like receptor (TLR)3 ligand, poly(I:C), were coadministered at the onset of the model, but not in established disease. Mice deficient in IFNαâ^¼ βR had an accelerated course of arthritis, and did not respond to poly(I:C). IKK[epsilon] null mice had a modest decrease in clinical arthritis compared with heterozygous mice. Low doses of IFNβ that were ineffective in wild type mice significantly decreased clinical arthritis in IKK[epsilon] null mice. Articular chemokine gene expression was reduced in the IKK[epsilon] â[euro]"/â[euro]" mice with arthritis and secreted IL1Ra (sIL1Ra) mRNA was significantly increased. Serum levels of IL1Ra were increased in low dose IFNβ-treated IKK[epsilon]â[euro]"/â[euro]" mice. Conclusions: Subtherapeutic doses of IFNβ enhance the anti-inflammatory effects of IKK[epsilon] deficiency, possibly by increasing production of IL1Ra and unmasking the antichemokine effects. Combination therapy with low dose IFNβ and an IKK[epsilon] inhibitor might improve efficacy of either agent alone and offers a novel approach to RA.
language: eng
source:
identifier: ISSN: 0003-4967
fulltext: no_fulltext
issn:
  • 0003-4967
  • 1468-2060
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.1430836
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_cross
recordidTN_cdi_proquest_journals_1777857511
sourceformatXML
sourcesystemPC
sourcerecordid4008482331
originalsourceidFETCH-LOGICAL-c741-655920d40f90e00e28336183bf5627b9f86936305efb0f02e019e9f9d69af9d90
addsrcrecordideNotkEFLAzEQhYMoWKtnrwHPWyebTTY5atFaKHiwB28huzupqW1Wk_TQf9Pf0l_mlgqPeTx4MwMfIfcMJoxx-WhjNykB1AS04EJekBGrpCpKkHBJRgDAi0rL-prcpLQeIiimRuTzYx8wrnzKvqUNBnQ-Ux8GuY3dbm3u457amL-izz7RZk-zjSvMPqzo_Hh4pt8-2IT0eKA2dMNaxugw9uGWXDm7SXj372OyfH1ZTt-KxftsPn1aFG1dsUIKoUvoKnAaEABLxblkijdOyLJutFNSc8lBoGvAQYnANGqnO6ntMDWMycP57E_sf3eYsln3uxiGj4bVda1ELRgbWuLcamOfUkRnWp9t9n3I0fqNYWBODM3A0JwYmjND-APQimYa
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1777857511
display
typearticle
titleSynergistic benefit in inflammatory arthritis by targeting I B kinase   and interferon
creatorM Corr ; D L Boyle ; L Ronacher ; N Flores ; G S Firestein
creatorcontribM Corr ; D L Boyle ; L Ronacher ; N Flores ; G S Firestein
descriptionObjectives: The IκB kinase (IKK)-related kinase IKK[epsilon] regulates type I interferon expression and responses as well as proinflammatory mediator production. We examined the role of IKK[epsilon] in arthritis and its ability to enhance the therapeutic response to systemic interferon (IFN) β therapy in passive murine K/BxN arthritis. Methods: IKK[epsilon]â[euro]"/â[euro]" , IFNαâ^¼ βRâ[euro]"/â[euro]" and wild type mice were given K/BxN serum and treated with polyinosinic polycytidylic acid (poly(I:C)), IFNβ, or normal saline. Clinical response and histological scores were assessed. Gene expression in the paws was measured by quantitative PCR. Serum interleukin 1a receptor agonist (IL1Ra) and IL10 were measured by ELISA and multiplex bead array. Results: Arthritis was almost completely blocked in wild type mice if arthritogenic K/BxN serum and the Toll-like receptor (TLR)3 ligand, poly(I:C), were coadministered at the onset of the model, but not in established disease. Mice deficient in IFNαâ^¼ βR had an accelerated course of arthritis, and did not respond to poly(I:C). IKK[epsilon] null mice had a modest decrease in clinical arthritis compared with heterozygous mice. Low doses of IFNβ that were ineffective in wild type mice significantly decreased clinical arthritis in IKK[epsilon] null mice. Articular chemokine gene expression was reduced in the IKK[epsilon] â[euro]"/â[euro]" mice with arthritis and secreted IL1Ra (sIL1Ra) mRNA was significantly increased. Serum levels of IL1Ra were increased in low dose IFNβ-treated IKK[epsilon]â[euro]"/â[euro]" mice. Conclusions: Subtherapeutic doses of IFNβ enhance the anti-inflammatory effects of IKK[epsilon] deficiency, possibly by increasing production of IL1Ra and unmasking the antichemokine effects. Combination therapy with low dose IFNβ and an IKK[epsilon] inhibitor might improve efficacy of either agent alone and offers a novel approach to RA.
identifier
0ISSN: 0003-4967
1EISSN: 1468-2060
2DOI: 10.1136/ard.2008.095356
3CODEN: ARDIAO
languageeng
publisherLondon: BMJ Publishing Group LTD
subjectArthritis ; Chemokines ; Cytokines ; Disease ; Gene expression ; Histology ; Inflammation ; Kinases ; Laboratory animals ; Ligands ; Proteins ; Rodents ; Software ; Tumor necrosis factor-TNF ; Variance analysis
ispartofAnnals of the rheumatic diseases, 2009-02-01, Vol.68 (2), p.257
rightsCopyright: 2009 2009 BMJ Publishing Group and European League Against Rheumatism
lds50peer_reviewed
citedbyFETCH-LOGICAL-c741-655920d40f90e00e28336183bf5627b9f86936305efb0f02e019e9f9d69af9d90
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
search
creatorcontrib
0M Corr
1D L Boyle
2L Ronacher
3N Flores
4G S Firestein
title
0Synergistic benefit in inflammatory arthritis by targeting I B kinase   and interferon
1Annals of the rheumatic diseases
descriptionObjectives: The IκB kinase (IKK)-related kinase IKK[epsilon] regulates type I interferon expression and responses as well as proinflammatory mediator production. We examined the role of IKK[epsilon] in arthritis and its ability to enhance the therapeutic response to systemic interferon (IFN) β therapy in passive murine K/BxN arthritis. Methods: IKK[epsilon]â[euro]"/â[euro]" , IFNαâ^¼ βRâ[euro]"/â[euro]" and wild type mice were given K/BxN serum and treated with polyinosinic polycytidylic acid (poly(I:C)), IFNβ, or normal saline. Clinical response and histological scores were assessed. Gene expression in the paws was measured by quantitative PCR. Serum interleukin 1a receptor agonist (IL1Ra) and IL10 were measured by ELISA and multiplex bead array. Results: Arthritis was almost completely blocked in wild type mice if arthritogenic K/BxN serum and the Toll-like receptor (TLR)3 ligand, poly(I:C), were coadministered at the onset of the model, but not in established disease. Mice deficient in IFNαâ^¼ βR had an accelerated course of arthritis, and did not respond to poly(I:C). IKK[epsilon] null mice had a modest decrease in clinical arthritis compared with heterozygous mice. Low doses of IFNβ that were ineffective in wild type mice significantly decreased clinical arthritis in IKK[epsilon] null mice. Articular chemokine gene expression was reduced in the IKK[epsilon] â[euro]"/â[euro]" mice with arthritis and secreted IL1Ra (sIL1Ra) mRNA was significantly increased. Serum levels of IL1Ra were increased in low dose IFNβ-treated IKK[epsilon]â[euro]"/â[euro]" mice. Conclusions: Subtherapeutic doses of IFNβ enhance the anti-inflammatory effects of IKK[epsilon] deficiency, possibly by increasing production of IL1Ra and unmasking the antichemokine effects. Combination therapy with low dose IFNβ and an IKK[epsilon] inhibitor might improve efficacy of either agent alone and offers a novel approach to RA.
subject
0Arthritis
1Chemokines
2Cytokines
3Disease
4Gene expression
5Histology
6Inflammation
7Kinases
8Laboratory animals
9Ligands
10Proteins
11Rodents
12Software
13Tumor necrosis factor-TNF
14Variance analysis
issn
00003-4967
11468-2060
fulltextfalse
rsrctypearticle
creationdate2009
recordtypearticle
recordideNotkEFLAzEQhYMoWKtnrwHPWyebTTY5atFaKHiwB28huzupqW1Wk_TQf9Pf0l_mlgqPeTx4MwMfIfcMJoxx-WhjNykB1AS04EJekBGrpCpKkHBJRgDAi0rL-prcpLQeIiimRuTzYx8wrnzKvqUNBnQ-Ux8GuY3dbm3u457amL-izz7RZk-zjSvMPqzo_Hh4pt8-2IT0eKA2dMNaxugw9uGWXDm7SXj372OyfH1ZTt-KxftsPn1aFG1dsUIKoUvoKnAaEABLxblkijdOyLJutFNSc8lBoGvAQYnANGqnO6ntMDWMycP57E_sf3eYsln3uxiGj4bVda1ELRgbWuLcamOfUkRnWp9t9n3I0fqNYWBODM3A0JwYmjND-APQimYa
startdate20090201
enddate20090201
creator
0M Corr
1D L Boyle
2L Ronacher
3N Flores
4G S Firestein
generalBMJ Publishing Group LTD
scope
03V.
17X7
27XB
388E
488I
58AF
68FE
78FH
88FI
98FJ
108FK
11ABUWG
12AZQEC
13BBNVY
14BENPR
15BHPHI
16BTHHO
17DWQXO
18FYUFA
19GHDGH
20GNUQQ
21HCIFZ
22K9-
23K9.
24LK8
25M0R
26M0S
27M1P
28M2P
29M7P
30PQEST
31PQQKQ
32PQUKI
33PRINS
34Q9U
sort
creationdate20090201
titleSynergistic benefit in inflammatory arthritis by targeting I B kinase   and interferon
authorM Corr ; D L Boyle ; L Ronacher ; N Flores ; G S Firestein
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c741-655920d40f90e00e28336183bf5627b9f86936305efb0f02e019e9f9d69af9d90
rsrctypearticles
prefilterarticles
languageeng
creationdate2009
topic
0Arthritis
1Chemokines
2Cytokines
3Disease
4Gene expression
5Histology
6Inflammation
7Kinases
8Laboratory animals
9Ligands
10Proteins
11Rodents
12Software
13Tumor necrosis factor-TNF
14Variance analysis
toplevelpeer_reviewed
creatorcontrib
0M Corr
1D L Boyle
2L Ronacher
3N Flores
4G S Firestein
collection
0ProQuest Central (Corporate)
1Health & Medical Collection
2ProQuest Central (purchase pre-March 2016)
3Medical Database (Alumni Edition)
4Science Database (Alumni Edition)
5STEM Database
6ProQuest SciTech Collection
7ProQuest Natural Science Collection
8Hospital Premium Collection
9Hospital Premium Collection (Alumni Edition)
10ProQuest Central (Alumni) (purchase pre-March 2016)
11ProQuest Central (Alumni Edition)
12ProQuest Central Essentials
13Biological Science Collection
14ProQuest Central
15Natural Science Collection
16BMJ Journals
17ProQuest Central Korea
18Health Research Premium Collection
19Health Research Premium Collection (Alumni)
20ProQuest Central Student
21SciTech Premium Collection
22Consumer Health Database (Alumni Edition)
23ProQuest Health & Medical Complete (Alumni)
24ProQuest Biological Science Collection
25Consumer Health Database
26Health & Medical Collection (Alumni Edition)
27Medical Database
28Science Database
29Biological Science Database
30ProQuest One Academic Eastern Edition
31ProQuest One Academic
32ProQuest One Academic UKI Edition
33ProQuest Central China
34ProQuest Central Basic
jtitleAnnals of the rheumatic diseases
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0M Corr
1D L Boyle
2L Ronacher
3N Flores
4G S Firestein
formatjournal
genrearticle
ristypeJOUR
atitleSynergistic benefit in inflammatory arthritis by targeting I B kinase   and interferon
jtitleAnnals of the rheumatic diseases
date2009-02-01
risdate2009
volume68
issue2
spage257
pages257-
issn0003-4967
eissn1468-2060
codenARDIAO
abstractObjectives: The IκB kinase (IKK)-related kinase IKK[epsilon] regulates type I interferon expression and responses as well as proinflammatory mediator production. We examined the role of IKK[epsilon] in arthritis and its ability to enhance the therapeutic response to systemic interferon (IFN) β therapy in passive murine K/BxN arthritis. Methods: IKK[epsilon]â[euro]"/â[euro]" , IFNαâ^¼ βRâ[euro]"/â[euro]" and wild type mice were given K/BxN serum and treated with polyinosinic polycytidylic acid (poly(I:C)), IFNβ, or normal saline. Clinical response and histological scores were assessed. Gene expression in the paws was measured by quantitative PCR. Serum interleukin 1a receptor agonist (IL1Ra) and IL10 were measured by ELISA and multiplex bead array. Results: Arthritis was almost completely blocked in wild type mice if arthritogenic K/BxN serum and the Toll-like receptor (TLR)3 ligand, poly(I:C), were coadministered at the onset of the model, but not in established disease. Mice deficient in IFNαâ^¼ βR had an accelerated course of arthritis, and did not respond to poly(I:C). IKK[epsilon] null mice had a modest decrease in clinical arthritis compared with heterozygous mice. Low doses of IFNβ that were ineffective in wild type mice significantly decreased clinical arthritis in IKK[epsilon] null mice. Articular chemokine gene expression was reduced in the IKK[epsilon] â[euro]"/â[euro]" mice with arthritis and secreted IL1Ra (sIL1Ra) mRNA was significantly increased. Serum levels of IL1Ra were increased in low dose IFNβ-treated IKK[epsilon]â[euro]"/â[euro]" mice. Conclusions: Subtherapeutic doses of IFNβ enhance the anti-inflammatory effects of IKK[epsilon] deficiency, possibly by increasing production of IL1Ra and unmasking the antichemokine effects. Combination therapy with low dose IFNβ and an IKK[epsilon] inhibitor might improve efficacy of either agent alone and offers a novel approach to RA.
copLondon
pubBMJ Publishing Group LTD
doi10.1136/ard.2008.095356